Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The carcinogenic properties of topical PUVA

A lifelong study in mice

  • 27 Accesses

Summary

The tumorigenic properties of topical methoxsalen (8-MOP) and trioxsalen (TMP) plus ultraviolet light A (UVA) were studied in NMRI female mice. The animals were treated three times weekly for 9 months, and followed up for 18 months. Acetonic solutions of TMP (0.1 mg in 0.2 ml) and 8-MOP (0.6 mg in 0.2 ml) were applied to the shaved back skin of the mice and irradiated with UVA. The doses needed to elicit equivalent phototoxic effects were 0.29 J/cm2 in the TMP group and 1.09 J/cm2 in the 8-MOP group. Papillomas, keratoacanthomas, and squamous cell carcinomas developed in the 8-MOP group only, and the first tumor was seen at 10 months after the beginning of the study. The results suggest that the carcinogenicity of these two modes of photochemotherapy may differ.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Berne B, Fischer T, Michaëlsson G, Norén P (1984) Long-term safety of trioxsalen bath PUVA treatment: an 8-year follow-up of 149 psoriasis patients. Photodermatology 1:18–22

  2. 2.

    Fitzpatrick TB, Arndt KA, ElMofty AM, Pathak MA (1966) Hydroquinone and psoralens in the therapy of hypermelanosis and vitiligo. Arch Dermatol 93:589–599

  3. 3.

    Frej JV, Stephens P (1968) The correlation of promotion of tumor growth and of induction of hyperplasia in epidermal two-stage carcinogenesis. Br J Cancer 22:83–92

  4. 4.

    Griffin AC, Hakim RE, Knox J (1958) The wave length effect upon erythemal and carcinogenic response in psoralen treated mice. J Invest Dermatol 31:289–295

  5. 5.

    Hakim RE, Griffin AC, Knox JM (1960) Erythema and tumor formation in methoxsalen-treated mice exposed to fluorescent light. Arch Dermatol 82:572–577

  6. 6.

    Hannuksela M, Karvonen J (1984) Topical trioxsalen PUVA therapy. Acta Dermatol Venereol (Stockh) 113:135–138

  7. 7.

    Hecker E, Kubinyi H (1965) Über die Wirkstoffe des Crotonöls. IV. Reindarstellung und Charakterisierung der entzündlichen und cocarcinogenen Wirkstoffe B1 und B2. Z Krebsforsch 67:176–191

  8. 8.

    Kirkland DJ, Creed KL, Mannisto P (1983) Comparative bacterial mutagenicity studies with 8-methoxypsoralen and 4,5′,8-trimethylpsoralen in the presence of near-ultraviolet light and in the dark. Mutat Res 116:73–82

  9. 9.

    Koulu LM, Jansén CT (1984) Skin phototoxicity variations during repeated bath PUVA exposures to 8-methoxypsoralen and trimethylpsoralen. Clin Exp Dermatol 9:64–69

  10. 10.

    Langner A, Wolska H, Marzulli FN, Jablonski S, Jarzabek-Chorzelska M, Glinski W, Pawinska M (1977) Dermal toxicity of 8-methoxypsoralen administered (by gavage) to hairless mice irradiated with long-wave ultraviolet light. J Invest Dermatol 69:451–457

  11. 11.

    Mandula BB, Pathak MA, Dudek G (1976) Photochemotherapy: Identification of a metabolite of 4,5′,8-trimethylpsoralen. Science 193:1131–1134

  12. 12.

    Mandula BB, Pathak MA, Nakayama Y, Davidson SJ (1978) Induction of mixed-function oxidases in mouse liver by psoralens. Br J Dermatol 99:687–692

  13. 13.

    O'Neal MA, Griffin AC (1957) The effect of oxypsoralen upon ultraviolet carcinogenesis in albino mice. Cancer Res 17:911–916

  14. 14.

    Pathak MA, Marciani MS, Guiotto A, Rodighiero G (1983) A study of the relationship between photosensitizing and therapeutic activity of 4,5′,8-trimethylpsoralen, and its major metabolite 4,8-dimethyl,5′-carboxypsoralen. J Invest Dermatol 81:533–539

  15. 15.

    Quinto I, Averbeck D, Moustacchi E, Hrisoho Z, Moron J (1984) Frameshift mutagenicity in Salmonella typhimurium of furocoumarins in the dark. Mutat Res 136:49–54

  16. 16.

    Salo OP, Lassus A, Taskinen J (1981) Trioxsalen bath plus UVA treatment of psoriasis. Acta Dermatol Venereol (Stockh) 61:551–554

  17. 17.

    Stenbäck F (1982) Health hazards from ultraviolet radiation. Public Health Reviews. Int Q 10:229–337

  18. 18.

    Stenbäck F, Garcia H, Shubik P (1974) The present status of the concept of promotion and cocarcinogenesis in the skin. In: Hombrugger F (ed) Physiopathology of cancer. Karger, Basel

  19. 19.

    Stern RS, Laird N, Melski J, Parrish JA, Fitzpatrick TB, Bleich HL (1984) Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 310:1156–1161

  20. 20.

    Urbach F (1959) Modification of ultraviolet carcinogenesis by photoactive agents. J Invest Dermatol 32:373–378

  21. 21.

    Väätäinen N, Hannuksela M, Karvonen J (1981) Long-term local trioxsalen photochemotherapy in psoriasis. Dermatologica 163:229–321

  22. 22.

    Yarosh DB, Johns V, Mufti S, Bernstein C, Bernstein H (1980) Inhibition of UV and psoralen-plus-light mutagenesis in phage T4 by gene 43 antimutator polymerase alleles. Photochem Photobiol 31:341–350

  23. 23.

    Yoon K (1982) Localized mutagenesis of the tetracycline promoter region in pBR322 by 4,5′,8-trimethylpsoralen. Mutat Res 93:253–262

  24. 24.

    Young AR, Magnus IA, Davies AC, Smith NP (1983) A comparison of the phototumorigenic potential of 8-MOP and 5-MOP in hairless albino mice exposed to solar simulated radiation. Br J Dermatol 108:507–518

Download references

Author information

Correspondence to M. Hannuksela.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hannuksela, M., Stenbäck, F. & Lahti, A. The carcinogenic properties of topical PUVA. Arch Dermatol Res 278, 347–351 (1986). https://doi.org/10.1007/BF00418161

Download citation

Key words

  • Methoxsalen
  • PUVA-therapy
  • Skin cancers
  • Carcinogenesis, experimental